FOR IMMEDIATE RELEASE
March 15, 2010
GLOBAL MARKET FOR THERAPIES FOR DEPRESSIVE AND ANXIETY DISORDERS TO BE WORTH $38.5 BILLION IN 2014
Wellesley, Mass. – According to a new technical market research report, THERAPIES FOR DEPRESSIVE AND ANXIETY DISORDERS (PHM056A) from BCC Research (www.bccresearch.com), the global market for products used in the fight against depressive and anxiety disorders will be worth an estimated $29.4 billion in 2009. That is expected to increase to $38.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 5.6%.
The market is broken down into antidepressants and antianxiety drugs. The antidepressants segment has the largest share of the market, worth an estimated $16.2 billion in 2009. This segment is expected to grow at a CAGR of 5.5% to reach more than $21.2 billion in 2014.
The antianxiety drugs segment was estimated to be worth $13.2 billion in 2009, and is expected to increase at a CAGR of 5.6 to reach $17.3 billion in 2014.
The objectives of the study are to present a comprehensive look at disorders that affect the mind, specifically that cause depression and anxiety. An overall discussion of mental disorders associated with depression and anxiety is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society.
The report identifies the different disorders that manifest with depressive and anxiety symptoms; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size, and market participants; and presents potential treatments in research and development.
In addition to pharmaceutical companies developing new products that will offer fewer side effects, better efficacy, and more convenient dosing, companies are revisiting products that are already established on the market in hopes of expanding the indications and increase usage of existing products.
Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of therapies for depressive and anxiety disorders must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.
Source: BCC Research
Therapies for Depressive and Anxiety Disorders( PHM056A )
Target Date: February 2010 Price: $5450.00
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: firstname.lastname@example.org as the source and publisher, along with report number, which can be found in the first paragraph of this release. Thank you.